Regenerative Medicine Market Overview, Driving Factors, Key Players and Forecast to 2024

Technological innovations in the area of stem cell therapy and tissue engineering has led to rapid growth of the regenerative medicine market size. The key factors which drive the growth of the global market include increase in the demand of orthopaedic surgeries, government healthcare reforms in certain countries such as the U.S. and Canada, aging population, rise in chronic diseases, increasing prevalence of bone and joint diseases, and innovations in nanotechnology that aids in drug delivery mechanism.

However, stringent regulations, ethical issues, and the risk of product failure and their recall are the key barriers for the growth of the regenerative medicine market. The cost of regenerative medicine treatment is significantly high and it is less effective in case of geriatric patients, which hinders the growth of the global market to some extent.


Globally, North America is the largest market for regenerative medicine followed by Europe. The largest regenerative medicine market size of North America is attributed to the high rate of incidence of cardiac disorders, autoimmune diseases, and increasing prevalence of cancer patients among the American population. Additionally, the involvement of government organization for funding in the area of R&D of regenerative medicines, technological advancement and other policies are driving the growth of the North American market.

Pre-Purchase inquiry at:

Key companies are acquiring other companies to strengthen their regenerative medicine market share. For instance, in August 2016, Medtronic Inc. had acquired Heart Ware International, Inc., that offers less-invasive, miniaturized, mechanical circulatory support (MCS) techniques as an advanced heart failure treatment. This acquisition was aimed at increasing the working efficiency of the company and to broaden its product portfolio.

Some of the other key players operating in the global market include Acelity L.P. Inc., NuVasive Inc., Vericel Corporation, Osiris therapeutics Inc., Integra Lifesciences Corporation, Stryker Corporation, Cook Biotech Incorporated, Organogenesis Inc., and Japan Tissue Engineering Co. Ltd.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s